Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986408 |
| Synonyms | |
| Therapy Description |
BMS-986408 inhibits DGKalpha and DGKzeta, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986408 | BMS 986408|BMS986408 | BMS-986408 inhibits DGKalpha and DGKzeta, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05407675 | Phase Ib/II | BMS-986408 + Ipilimumab + Nivolumab BMS-986408 + Nivolumab BMS-986408 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | CHE | CAN | 0 |